Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
- Sponsor
- Rigshospitalet, Denmark
- Study ID
- NCT00272558
- Phase
- PHASE2
- Status
- Completed
Conditions
- Malignant Pleural Mesothelioma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Carboplatin and Vinorelbine — DRUG
Study Details
The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma.
Key Dates
- Start date
- Sep 30, 2004
- Status verified
- Sep 2009
- Primary completion
- Sep 30, 2009
- Completion
- Sep 30, 2009
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Response
Related Studies
- OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint InhibitionPHASE2 · Not Yet Recruiting · Oncotelic Inc. · Philadelphia, Pennsylvania
- Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural MesotheliomaRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey